CJC 1295 No DAC 5 mg/Ipamorelin 5 mg

CJC-1295 no DAC + Ipamorelin Blend by Dragon Pharma

This CJC-1295 no DAC / Ipamorelin blend combines two complementary GH secretagogues in a single 10mg vial — a modified GHRH analogue and a selective ghrelin receptor agonist working through different receptors to produce synergistic GH release. The "no DAC" designation is critical to understanding how this blend differs from CJC-1295 with DAC, and why its dosing protocol is fundamentally different.

Also searched as: CJC-1295 no DAC Ipamorelin blend, Mod GRF 1-29 Ipamorelin, CJC Ipa blend Dragon Pharma.

CJC-1295 no DAC vs CJC-1295 with DAC — The Critical Distinction

This is the most important and most frequently misunderstood aspect of CJC-1295 products, and a genuine information gap in most competitor content:

The key insight: CJC-1295 no DAC and Ipamorelin are ideally paired together because they share similar short half-lives (~30 min and ~2 hours respectively), both produce GH release through distinct receptor pathways, and when injected simultaneously, their combined effect produces a sharp, synergistic GH pulse that more closely mimics the body's natural pulsatile GH secretion pattern. CJC-1295 with DAC's week-long half-life creates a different pharmacodynamic profile that does not pair as naturally with Ipamorelin's short-acting pulsatile mechanism.

Why GHRH + GHRP Synergy Produces More GH Than Either Alone

The two components work on fundamentally different receptor systems in the pituitary:

• CJC-1295 no DAC binds GHRH receptors (GHRHR) on pituitary somatotroph cells, stimulating GH synthesis and release through cAMP-mediated pathways
• Ipamorelin binds ghrelin receptors (GHS-R1a) on the same somatotroph cells, stimulating GH release through phospholipase C / IP3 pathways — a completely separate signalling cascade
• When both receptors are activated simultaneously, the two pathways interact in a supra-additive manner — the combined GH response is significantly greater than the sum of each compound used alone
• Research has demonstrated that GHRH + GHRP combinations produce 3-5× the GH output of either compound alone at equivalent doses

Effects and Benefits

• Synergistic GH release significantly greater than either peptide alone — estimated 3-5× increase over monotherapy
• Pulsatile GH pattern closely mimicking physiological nocturnal GH secretion
• Improved sleep quality — nocturnal GH pulses occur during slow-wave sleep; amplifying this pulse improves sleep depth
• Body recomposition support through elevated GH and downstream IGF-1
• No suppression of natural testosterone — does not require Post Cycle Therapy
• No cortisol or prolactin elevation — Ipamorelin's hallmark selectivity is preserved in the blend

Dosage and Administration

Because both components have short half-lives, they must be dosed more frequently than CJC-1295 with DAC — typically 2-3 times daily for maximum effect. The most important dose is pre-sleep on an empty stomach, which amplifies the largest natural GH pulse of the day. Insulin significantly blunts GH release — dosing within 2 hours of food reduces the GH response substantially. With 10mg total vial content, dosing at 200mcg per injection provides approximately 25 injections from a single vial at once-daily dosing, or ~8 injections at three-times-daily dosing.